Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study

Key Points

• The aim is to evaluate the real-world effectiveness and safety of faricimab for treating neovascular age-related macular degeneration (nAMD).
• Analyzed 1-year data from patients treated with faricimab
• Evaluated visual outcomes and treatment patterns
• Assessed safety profiles of the intervention
• Faricimab showed significant effectiveness in improving visual outcomes at 12 months
• Treatment demonstrated durability over the year
• Safety profile was consistent with existing data on faricimab